Showing results (31-40 of 242) with videos related to
Sort By:
Pageof 25
Post Reproductive Health|February 18, 2016
The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal womenBilal Chughtai, James C Forde, Jessica Buck, et al.World Journal of Urology|March 26, 2013
Use of the Bulbocavernosus Reflex System in assessing voiding dysfunctionMelissa A Laudano, Bilal Chughtai, Richard K Lee, et al.The Canadian Journal of Urology|April 30, 2014
Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasiaBilal Chughtai, Claire Dunphy, Richard Lee, et al.Journal of Endourology|December 28, 2012
Comparison of techniques for transurethral laser prostatectomy: standard photoselective vaporization of the prostate versus transurethral laser enucleation of the prostateDean S Elterman, Bilal Chughtai, Richard Lee, et al.The Journal of Urology|July 28, 2011
Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasiaDoreen E Chung, James S Wysock, Richard K Lee, et al.Journal of Endourology|October 30, 2014
Trends and Utilization of Laser Prostatectomy in Ambulatory Surgical Procedures for the Treatment of Benign Prostatic Hyperplasia in New York State (2000-2011)Bilal I Chughtai, Vannita Simma-Chiang, Richard Lee, et al.Clinical Therapeutics|July 16, 2002
A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditionsAlexis E TeF1000Research|September 12, 2019
Recent advances in prostatectomy for benign prostatic hyperplasiaAlexis E TeReviews in Urology|December 19, 2006
The Next Generation in Laser Treatments and the Role of the GreenLight High-Performance System LaserAlexis E TeThe Journal of Urology|July 24, 2012
Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancerSteven A Kaplan, Richard K Lee, Doreen E Chung, et al.Pageof 25